Journal article
Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program
AL Morey, B Brown, G Farshid, SB Fox, GD Francis, G McCue, V von Neumann-Cosel, M Bilous
Pathology | ELSEVIER | Published : 2016
Abstract
Appropriate and accurate determination of HER2 status in women with breast cancer is critical for stratifying anti-HER2 therapies, and for access to subsidised treatment in the Australian setting. We conducted a regulated, nationwide program providing HER2 in situ hybridisation (ISH) testing for patients with newly diagnosed breast cancer. Cases with equivocal or non-diagnostic ISH test results at the local laboratory were sent to a high volume central testing laboratory for analysis using fluorescence ISH (FISH). We tested 78,408 early breast cancers and 3469 metastatic cancers using ISH. Of these, 12,405 early breast cancers (15.8%) and 798 metastatic cancers (23.0%) were HER2 positive. Du..
View full abstractGrants
Funding Acknowledgements
Medical writing services from WriteSource Medical Pty Ltd were funded by Roche Products Pty Ltd. This study was funded by Roche Products Pty Ltd, Australia. ALM has held a consultancy/advisory role with Roche Products Pty Ltd and Pfizer; GF has held a consultancy/advisory role with the Australian HER2 Advisory Board; SBF has held a consultancy/advisory role with Roche Products Pty Ltd; GDF has received honoraria from Roche Products Pty Ltd and has held a consultancy/advisory role with Roche Products Pty Ltd, Astra Zeneca, Merck Serrono and Pfizer; GM has held a consultancy role with Roche Products Pty Ltd; VvN-C is an employee of Roche Products Pty Ltd, which markets trastuzumab; MB has held a consultancy/advisory role with F. Hoffmann-La Roche.